Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kura Oncology, Inc. - Common Stock (NQ:KURA)

8.825 +0.655 (+8.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kura Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential. 
Via Benzinga
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Uncovering Potential: Kura Oncology's Earnings Preview
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
2 Incredible Growth Stocks to Buy Hand Over Fist
These two healthcare growth stocks could have a lot more room to run. 
Via The Motley Fool
Kura (KURA) Revenue Drops 61%
Via The Motley Fool
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe
Via Stocktwits
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025. 
Via Benzinga
These stocks are moving in today's after hours session
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Kura Oncology Inc. (NASDAQ: KURA) is a Stock Spotlight on 3/6
Via Investor Brand Network
Kura Oncology: Q4 Earnings Insights
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
 
Via Benzinga
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
 
Via Benzinga
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
Instead of seeking a takeover, the company inked a deal worth up to $1.53 billion for its lead asset. 
Via Investor's Business Daily
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Earnings Outlook For Kura Oncology
 
Via Benzinga
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
KURA Stock Earnings: Kura Oncology Beats EPS for Q2 2024
KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys
Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position. 
Via InvestorPlace
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
KURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024
KURA stock results show that Kura Oncology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.